Stopping RAS Inhibitors After AKI Ups Risk for Adverse Events
Findings may aid physicians in their clinical decision-making in the absence of randomized clinical trial data, according to investigators.
Diagnosis & Disease Information
MRA Treatment Ups Hyperkalemia Risk, but Not Death in CKD
Mineralocorticoid receptor antagonist treatment is often not recommended in patients with advanced kidney disease due to perceived risk of hyperkalemia and death, investigators noted.
Chronic Kidney Disease Is More Common in the Cancer Population
In a study conducted in Romania, the prevalence of CKD in patients with cancer was 11.9% compared with 8.8% in the general population.
Dapagliflozin Slows FSGS Progression
Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.
Kidney Stone Risk Higher Among Men Than Women
Modifiable risk factors accounted for only a fraction of the difference in stone rates between the sexes, according to investigators.
Sarcopenia Common, Potentially Life-Threatening in Nondialysis CKD
The prevalence of CKD-related sarcopenia may be higher than ageing-related sarcopenia.
Belimumab Shows Longer-Term Safety, Efficacy in Lupus Nephritis
The proportion of patients with lupus nephritis achieving renal response with belimumab increased during a 6-month extension study.
IL-6 Levels Linked With Progression of Diabetic Kidney Disease
In a small trial, patients with the highest tertile of IL-6 experienced significantly faster progression of diabetic kidney disease.
High, Low Uric Acid Levels Increase Chronic Kidney Disease Risk
In a study of middle-aged adults, serum uric acid levels less than 4.0 and 10.0 mg/dL or higher in men and less than 4.0 and 8.0 mg/dL or higher in women were significantly associated with increased risks for chronic kidney disease.
Renoprotective Effect of SGLT2 Inhibitors Mediated Largely by Hematocrit
Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.
- Loading...
Loading...
Next post in Anemia
Loading... 
Loading...